Taming molecular flexibility to tackle rare diseases

Biochimie

Volumn 113, Issue , 2015, Pages 54-58

  Cubellis, Maria Vittoria ^a   Baaden, Marc ^b   Andreotti, Giuseppina ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b France   (France)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Diagnostic use; Disease; Molecular dynamics; Protein stability

Indexed keywords

ALPHA GALACTOSIDASE;

ARTICLE; DISEASE SEVERITY; ENZYME ACTIVITY; FABRY DISEASE; GENETIC CORRELATION; GENOTYPE; IN VIVO STUDY; MISSENSE MUTATION; MOLECULAR DYNAMICS; MOLECULAR STABILITY; NONSENSE MUTATION; PROTEIN HOMEOSTASIS; PROTEIN STABILITY; PROTEIN STRUCTURE; CHEMISTRY; ENZYMOLOGY; GENETICS; HUMAN; MOLECULAR DOCKING; MUTATION;

ALPHA-GALACTOSIDASE; FABRY DISEASE; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTATION;

EID: 84927663016     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2015.03.018     Document Type: Article

References (31)

1. P. Yue, Z. Li, and J. Moult Loss of protein structure stability as a major causative factor in monogenic disease J. Mol. Biol. 353 2005 459 473
2. J. Aymami, X. Barril, L. Rodriguez-Pascau, and M. Martinell Pharmacological chaperones for enzyme enhancement therapy in genetic diseases Pharm. Pat. Anal. 2 2013 109 124
3. L.M. Ryno, R.L. Wiseman, and J.W. Kelly Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases Curr. Opin. Chem. Biol. 17 2013 346 352
4. D.P. Germain Fabry disease Orphanet J. Rare Dis. 5 2010 30
5. J.Q. Fan, S. Ishii, N. Asano, and Y. Suzuki Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nat. Med. 5 1999 112 115
6. A. Frustaci, C. Chimenti, R. Ricci, L. Natale, M.A. Russo, M. Pieroni, C.M. Eng, and R.J. Desnick Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy N. Engl. J. Med. 345 2001 25 32
7. M. Cammisa, A. Correra, G. Andreotti, and M.V. Cubellis Fabry-CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones Orphanet J. Rare Dis. 8 2013 111
8. A.I. Guce, N.E. Clark, J.J. Rogich, and S.C. Garman The molecular basis of pharmacological chaperoning in human alpha-galactosidase Chem. Biol. 18 2011 1521 1526
9. G. Andreotti, V. Citro, A. Correra, and M.V. Cubellis A thermodynamic assay to test pharmacological chaperones for Fabry disease Biochim. Biophys. Acta 1840 2014 1214 1224
10. HGMD HGMD 2011 http://www.hgmd.cf.ac.uk/ac/index.php
11. J. Wang, P. Cieplak, and P.A. Kollman How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 21 2000 1049 1074
12. E. Krieger, T. Darden, S.B. Nabuurs, A. Finkelstein, and G. Vriend Making optimal use of empirical energy functions: force-field parameterization in crystal space Proteins 57 2004 678 683
13. E. Krieger, G. Koraimann, and G. Vriend Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field Proteins 47 2002 393 402
14. D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, and H.J. Berendsen GROMACS: fast, flexible, and free J. Comput Chem. 26 2005 1701 1718
15. M.V. Cubellis, F. Cailliez, and S.C. Lovell Secondary structure assignment that accurately reflects physical and evolutionary characteristics BMC Bioinforma. 6 Suppl 4 2005 S8
16. M. Cammisa, A. Correra, G. Andreotti, and M.V. Cubellis Identification and analysis of conserved pockets on protein surfaces BMC Bioinforma. 14 Suppl 7 2013 S9
17. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera-a visualization system for exploratory research and analysis J. Comput Chem. 25 2004 1605 1612
18. S. Saito, K. Ohno, J. Sese, K. Sugawara, and H. Sakuraba Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information J. Hum. Genet. 55 2010 175 178
19. M. Rigoldi, D. Concolino, A. Morrone, F. Pieruzzi, R. Ravaglia, F. Furlan, F. Santus, P. Strisciuglio, G. Torti, and R. Parini Intrafamilial phenotypic variability in four families with Anderson-Fabry disease Clin. Genet. 86 3 2014 Sep 258 263
20. M.H. Branton, R. Schiffmann, S.G. Sabnis, G.J. Murray, J.M. Quirk, G. Altarescu, L. Goldfarb, R.O. Brady, J.E. Balow, H.A. Austin Iii, and J.B. Kopp Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course Med. Baltim. 81 2002 122 138
21. M. Ries, and A. Gal Genotype-phenotype Correlation in Fabry Disease 2006
22. G. Andreotti, V. Citro, A. De Crescenzo, P. Orlando, M. Cammisa, A. Correra, and M.V. Cubellis Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests Orphanet J. Rare Dis. 6 2011 66
23. J. Lukas, A.K. Giese, A. Markoff, U. Grittner, E. Kolodny, H. Mascher, K.J. Lackner, W. Meyer, P. Wree, V. Saviouk, and A. Rolfs Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease PLoS Genet. 9 2013 e1003632
24. J.Y. Park, G.H. Kim, S.S. Kim, J.M. Ko, J.J. Lee, and H.W. Yoo Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease Exp. Mol. Med. 41 2009 1 7
25. M. Shimotori, H. Maruyama, G. Nakamura, T. Suyama, F. Sakamoto, M. Itoh, S. Miyabayashi, T. Ohnishi, N. Sakai, M. Wataya-Kaneda, M. Kubota, T. Takahashi, T. Mori, K. Tamura, S. Kageyama, N. Shio, T. Maeba, H. Yahagi, M. Tanaka, M. Oka, H. Sugiyama, T. Sugawara, N. Mori, H. Tsukamoto, K. Tamagaki, S. Tanda, Y. Suzuki, C. Shinonaga, J. Miyazaki, S. Ishii, and F. Gejyo Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone Hum. Mutat. 29 2008 331
26. S.H. Shin, S. Kluepfel-Stahl, A.M. Cooney, C.R. Kaneski, J.M. Quirk, R. Schiffmann, R.O. Brady, and G.J. Murray Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone Pharmacogenet Genomics 18 2008 773 780
27. M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A. Ponzone, and R.J. Desnick High incidence of later-onset fabry disease revealed by newborn screening Am. J. Hum. Genet. 79 2006 31 40
28. X. Wu, E. Katz, M.C. Della Valle, K. Mascioli, J.J. Flanagan, J.P. Castelli, R. Schiffmann, P. Boudes, D.J. Lockhart, K.J. Valenzano, and E.R. Benjamin A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease Hum. Mutat. 32 2011 965 977
29. S. Ishii, H.H. Chang, K. Kawasaki, K. Yasuda, H.L. Wu, S.C. Garman, and J.Q. Fan Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin Biochem. J. 406 2007 285 295
30. R.L. Lieberman, J.A. D'Aquino, D. Ringe, and G.A. Petsko Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 48 2009 4816 4827
31. G. Andreotti, M.R. Guarracino, M. Cammisa, A. Correra, and M.V. Cubellis Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study Orphanet J. Rare Dis. 5 2010 36